Fgfr4-Car T Cells
Rhabdomyosarcoma
National Cancer Institute (NCI)Cell therapyPhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 73/ 100
Competitive context
58 Active assets in the Rhabdomyosarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Eisai Inc. | Phase 2 | BBB |
Ipilimumab Children's National Research Institute | Phase 2 | BB |
CALCIUM PHOSPHATE Children's Oncology Group | Phase 3 | BB |
Irinotecan Milton S. Hershey Medical Center | Phase 2 | BB |
Eloxatin National Cancer Institute (NCI) | Phase 2 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →